Spotlight: Value Assessment

Welcome to The Evidence Base spotlight on ‘Value Assessment’, where we will be featuring expert insights, news, articles and more to help our readers stay up-to-date with the latest discussions surrounding the approach, applicability and methodology used to assess the value of a health care treatment or service.

Read our Expert Insight interviews here:

Photo of Jason Spangler, of Innovation and Value Initiative discussing the impact of the Inflation Reduction Act on drug development and patients
Impact of the Inflation Reduction Act on drug development and patients: an interview with Jason Spangler, Innovation and Value Initiative

 

 

 

Headshots of Corey Ford and Kim Westrich discussing the Inflation Reduction Act

Impact of the Inflation Reduction Act on US health care: an interview with Corey Ford and Kimberly Westrich, Xcenda

 

 

 

Understanding the value assessment landscape in the United States: an interview with Emily Ortman, PhRMA Foundation

 

 

 

Assessing the value of digital health technologies: an interview on the experience of Germany and England

 

 

 

The patient voice in ICER value assessments: an interview with Yvette Venable

 

 

 

Ask the Experts: valuing new pharmaceuticals and sharing this value

 

 

 

 

Get in touch to discuss the opportunities available to share your expertise, contribute to this theme or to become a theme sponsor.

 

Find articles published in the Journal of Comparative Effectiveness Research

Cost standard set program: moving forward to standardization of cost assessment based on clinical condition
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications
The next generation of rare disease drug policy: ensuring both innovation and affordability
Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals
Assessing potential cures: are there distinctive elements of value beyond health gain?
Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit

Discover more from The Evidence Base here

Drug Price Negotiation Program
PhRMA joins legal battle against Medicare drug pricing provisions in the Inflation Reduction Act
Inflation Reduction Act in numbers. smart prices act CMS Medicare
The Inflation Reduction Act in numbers: estimating the impact of implementing Medicare drug pricing policies on the US healthcare ecosystem
ICER seeking public input on proposed changes to its value assessment framework
Medicare Part B prescription drugs
CMS expands lists of Part B prescription drugs subject to the Medicare Prescription Drug Inflation Rebate Program
Merck IRA lawsuit
Merck files lawsuit against US government over Medicare Drug Price Negotiation Program – will others follow?
Medical pills on one hundred dollar bills
The debate over QALYs in US drug value assessments continues
What next for QALYs in US drug value assessments?
Digital image of a brain showing cogs
NICE issues first guidance under early value assessment on digital mental health technologies for children and young people
trial design
ICER pilot project to use real-world evidence in hereditary angioedema treatments value assessment update
Look behind the lecture: maintaining a STEDI reserve of novel antibiotics – the importance of expanded value assessment
QALYs in cancer: are they meaningfully counted?
Valuing health outcomes in cost–effectiveness analyses: health years in total vs QALYs
ISPOR 2020 – inside the third plenary: leaving the QALY behind…but not completely
Look behind the lecture: the controversial QALY